Benefit-Risk And Medical Costs of Rivaroxaban 15mg Versus Vitamin K Antagonists From A French Nationwide Cohort of 220,000 Patients With Non-Valvular Atrial Fibrillation
Oct 1, 2017, 00:00
10.1016/j.jval.2017.08.1191
https://www.valueinhealthjournal.com/article/S1098-3015(17)31525-5/fulltext
Title :
Benefit-Risk And Medical Costs of Rivaroxaban 15mg Versus Vitamin K Antagonists From A French Nationwide Cohort of 220,000 Patients With Non-Valvular Atrial Fibrillation
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(17)31525-5&doi=10.1016/j.jval.2017.08.1191
First page :
A608
Section Title :
Disease-Specific Studies
Open access? :
No
Section Order :
1137